Cost-Effectiveness of the Next Generation Nonavalent Human Papillomavirus Vaccine in the Context of Primary Human Papillomavirus Screening in Australia: A Comparative Modelling Analysis
The Lancet Public Health - United Kingdom
doi 10.1016/s2468-2667(16)30019-6
Full Text
Open PDFAbstract
Available in full text
Date
December 1, 2016
Authors
Publisher
Elsevier BV